

World Market for Addiction Disorders, 2009 – 2016

Future Therapies for Substance Dependence and Impulse Control

List of Tables

- Table 1.1 Neurotransmitter Systems Associated with Addiction
- Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
- Table 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009 (000' users)
- Table 1.4 Estimated Incidence for Addiction Disorders in North America, Europe and Japan, 2009 (incidence in 000s)
- Table 2.1 Market Synopsis for Addiction Disorders: Current data
- Table 2.2 Estimated Global Sales (US\$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2008-2016
- Table 3.1 Physiological Consequences of the Disulfiram-Alcohol Reaction
- Table 5.1 Estimated Sales (US\$) and Annual Growth (%) of Smoking Cessation Therapies, 2008-2016
- Table 6.1 Drugs in Development/Trials for Alcohol Dependence, 2009
- Table 6.2 Drugs in Development/Trials for Cocaine Dependence, 2009
- Table 6.3 Drugs in Development/Trials for Cannabis Dependence, 2009
- Table 6.4 Drugs in Development/Trials for Amphetamine and Phencyclidine Dependencies, 2009
- Table 6.5 Drugs in Development/Trials for Opioid Dependence, 2009
- Table 6.6 Drugs in Development/Trials for Impulse Control Disorders, 2009
- Table 6.7 Drugs in Development/Trials for Tobacco Addiction, 2009
- Table 7.1 Estimated Global Drug Market (US\$m) and Growth Rate (%) for Addiction Pharmacotherapies, 2008-2016
- Table 7.2 Therapy Area Forecasts for the World Addiction Disorders Market, 2016 and 2025

List of Figures

- Figure 1.1 Estimated Prevalence of Substance Misuse in United States, 2009
- Figure 1.2 Estimated Prevalence of Substance Misuse in Canada, 2009
- Figure 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009
- Figure 1.4 Estimated Prevalence of Substance Misuse in Japan, 2009
- Figure 2.1 Estimated Sales (US\$) of Addiction Drugs Segmented by Therapeutic Area, 2008-2016
- Figure 2.2 Estimated Global Sales (US\$) of Leading Addiction Drugs by Therapy Area, 2009 & 2016
- Figure 7.1 Comparative Analysis of Leading Addiction Pharmacotherapies, 2008-2016 (US\$m)
- Figure 7.2 Key Addiction Disorder Pharmacotherapy Prospects, 2009